The partnership enables the two companies to deliver end-to-end services from initial drug discovery through to early and late phase manufacturing.
The newly formed alliance means that customers of both Molecular Profiles and Onyx Scientific will have access to a wider range of services with the added benefit of a consistent team and delivery. The complementary alliance benefits from Onyx Scientific's specialism in active pharmaceutical ingredient (API) production and initial solid state screening, combined with Molecular Profiles' expertise in formulation and analytical development and early phase clinical trial manufacturing. Onyx Scientific also has sites in India providing customers with late stage clinical trial and commercial manufacturing services, completing the full service offering and accelerating drug candidates from discovery through to manufacture.
As the services offered by the two companies are well aligned, including a shared expertise in the area of solid state characterization, customers can expect a seamless and fully integrated service throughout the full drug discovery, development and manufacturing process. Customers also have the flexibility to select individual services from the full range to match their specific requirements.
Denise Bowser, Commercial Director at Onyx Scientific comments: “We are excited that the combination of the two companies will be able to offer customers the full range of chemistry and formulations services. Technical teams across these two best-in-class organisations will be routinely working together and our customers can rest assured that they will receive a seamless service throughout their drug discovery and development programmes.”
Claire Madden-Smith, Commercial Director at Molecular Profiles comments: “We are delighted to have partnered with Onyx Scientific and look forward to realising the benefits of this strategic alliance. Our customers are now able to access services ranging from API production through to formulation development and late stage manufacturing, providing flexibility and the opportunity to experience a consistent delivery across these stages.”
The newly formed alliance means that customers of both Molecular Profiles and Onyx Scientific will have access to a wider range of services with the added benefit of a consistent team and delivery. The complementary alliance benefits from Onyx Scientific's specialism in active pharmaceutical ingredient (API) production and initial solid state screening, combined with Molecular Profiles' expertise in formulation and analytical development and early phase clinical trial manufacturing. Onyx Scientific also has sites in India providing customers with late stage clinical trial and commercial manufacturing services, completing the full service offering and accelerating drug candidates from discovery through to manufacture.
As the services offered by the two companies are well aligned, including a shared expertise in the area of solid state characterization, customers can expect a seamless and fully integrated service throughout the full drug discovery, development and manufacturing process. Customers also have the flexibility to select individual services from the full range to match their specific requirements.
Denise Bowser, Commercial Director at Onyx Scientific comments: “We are excited that the combination of the two companies will be able to offer customers the full range of chemistry and formulations services. Technical teams across these two best-in-class organisations will be routinely working together and our customers can rest assured that they will receive a seamless service throughout their drug discovery and development programmes.”
Claire Madden-Smith, Commercial Director at Molecular Profiles comments: “We are delighted to have partnered with Onyx Scientific and look forward to realising the benefits of this strategic alliance. Our customers are now able to access services ranging from API production through to formulation development and late stage manufacturing, providing flexibility and the opportunity to experience a consistent delivery across these stages.”
Companies in this article
